CCIA
AMRX icon

Campbell & Co Investment Adviser’s Amneal Pharmaceuticals AMRX Stock Holding History

Campbell & Co Investment Adviser’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-60,620
Closed -$754K – 1022
2026
Q1 		$754K Buy
+60,620
New +$814K 0.04% 603
2022
Q3 		– Sell
-28,223
Closed -$90K – 698
2022
Q2 		$90K Buy
28,223
+1,689
+6% +$6.12K 0.02% 645
2022
Q1 		$111K Sell
26,534
-166
-0.6% -$735 0.03% 662
2021
Q4 		$128K Buy
+26,700
New +$133K 0.04% 571

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Campbell & Co Investment Adviser's AMRX Position: Q2 2026 in Review

Campbell & Co Investment Adviser sold out of Amneal Pharmaceuticals (AMRX) in Q2 2026, closing a stake of 60,620 shares — an estimated $754K sold.

Campbell & Co Investment Adviser first reported a position in AMRX in Q4 2021 and held it in 4 quarters. The position peaked at $754K in Q1 2026. 311 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

  • Campbell & Co Investment Adviser reported no remaining Amneal Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 60,620 Amneal Pharmaceuticals shares in Q2 2026, an estimated $754K.
  • Campbell & Co Investment Adviser first reported a position in Amneal Pharmaceuticals in Q4 2021 and held it in 4 quarters.
  • Campbell & Co Investment Adviser's Amneal Pharmaceuticals position peaked at $754K in Q1 2026.
  • 311 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2026, filed 3 Aug 2026.